Although mitochondrial transcription factor A (TFAM) is a protective component of mitochondrial DNA and a regulator of calcium and reactive oxygen species (ROS) production, the mechanism remains unclear. In heart failure (HF), TFAM is significantly decreased and cardiomyocyte instability ensues. TFAM inhibits Nuclear Factor of Activated T cells (NFAT), which reduces ROS production; additionally, TFAM transcriptionally activates SERCA2a to decrease free calcium. 
Although mitochondrial transcription factor A (TFAM) is a protective component of mitochondrial DNA and a regulator of calcium and reactive oxygen species (ROS) production, the mechanism remains unclear. In heart failure (HF), TFAM is significantly decreased and cardiomyocyte instability ensues. TFAM inhibits Nuclear Factor of Activated T cells (NFAT), which reduces ROS production; additionally, TFAM transcriptionally activates SERCA2a to decrease free calcium.
Therefore, decreasing TFAM vastly increases protease expression and hypertrophic factors, leading to cardiomyocyte functional decline. To examine this hypothesis, treatments of 1.0 micrograms of a TFAM vector and 1.0 micrograms of a CRISPR-Cas9 TFAM plasmid were administered to HL-1 cardiomyocytes via lipofectamine transfection. Western blotting and confocal microscopy analysis show that CRISPR-Cas9 knockdown of TFAM significantly increased proteases Calpain1, MMP9 and regulators Serca2a, and NFAT4 protein expression. CRISPR knockdown of TFAM in HL-1 D r a f t
Introduction
TFAM is a promoter-specific enhancer of mtDNA, regulator of mitochondrial genes and mtDNA copy number, and a physical protector of mtDNA (Ekstrand et al. 2004; Kunkel et al. 2016) . TFAM packages single copies of mtDNA, creating a mitochondrial nucleoid (Kunkel et al. 2015b; Wang et al. 1999) . TFAM is transported from the nucleus into the mitochondria by chaperone HSP70 (Santos et al. 2014) . Peroxidase enzymes reside within the nucleoid structure, mitigating oxidative damage to mitochondrial DNA (Larsson et al. 1998; Wang et al. 1999 ).
TFAM's physical protective function contributes to the mitigation of molecular abnormalities within the physiological myocardium, and in pathologies such as heart failure, TFAM is decreased. We seek to describe TFAM's effects on protease/hypertrophic molecular expression when influenced by hydrogen peroxide, TFAM overexpression, and CRISPR/Cas9 vector for TFAM knockdown.
TFAM's regulatory function to increase Serca2a transcriptional activity poses insight into its therapeutic potential (Watanabe et al. 2011) . Serca2a, an ATP-dependent calcium transporter, reduces free cytoplasmic calcium by storing it in the sarcoplasmic reticulum (Kunkel et al. 2015b ). Serca2a knockout models result in Heart Failure; Serca2a activity is significant for cardiomyocyte performance and contains translational components (Heinis et al. 2013; Lipskaia et al. 2010; Park and Oh 2013; Sikkel et al. 2014; Zsebo et al. 2014 ). TFAM's regulation of Serca2a decreases cytoplasmic calcium levels, effectively decreasing protease Calpain1 expression. Calcium-driven calpain proteases are responsible for the proteolytic degradation of both contractile and cytosolic proteins (Kunkel et al. 2015a) . Studies show that calpain upregulation is a major factor in cardiomyocyte functional decline (Takahashi et al. 2006) . Physical tethering interactions between the mitochondria and the sarcoplasmic reticulum play a role in calcium regulation (Chen et al. 2012; Li et al. 2015 ).
TFAM's protective function to inhibit NFAT expression reduces cardiomyocyte hypertrophy (Fujino et al. 2012 ). NFAT transcriptionally activates hypertrophic genes. The calcium-calmodulin-calcineurin cascade plays a role in the activation of T cells and related cytokines (Vandewalle et al. 2014 (Givvimani et al. 2012 ) and described MMP upregulation in heart failure as it pertains to ROS generation (Kunkel et al. 2015a ).
Although MMP 2 & 9 have increased activity in all cardiomyopic states (dilated, ischemic and inflammatory), MMP9 has the highest up-regulation in heart failure related cardiomyopathies (Romanic et al. 2001 ). Oxidative stress is evidently activating catabolic/proteolytic pathways, such as MMPs, in heart failure models. MMP9 is notably upregulated in pathological conditions of cardiovascular diseases (Iyer et al. 2016) . In an earlier study, Siwik et al found that hydrogen peroxide oxidative stress induced MMP9 activity (Siwik et al. 2001) . We have found that MMP9 triggers the signaling cascade leading to pathological cardiac remodeling in human heart end-stage heart failure (Moshal et al. 2006) . Additionally, we have described the results of MMP9 knockout models and the ameliorating affects post AVF induced Heart Failure (Moshal et al. 2008) . ROS-induced MMP9 is highly expressed in pathological human hearts (Moshal et al. 2006) .
Using CRISPR technology, we analyzed the effects of knocking down TFAM in HL-1 cardiomyocytes. This study was performed to observe the effects of TFAM vector treatments on protease/hypertrophic expression. Studies have shown that neonatal ablation of TFAM results in decreased mitochondrial biogenesis and death (Larsson et al. 1998) . Down regulation of TFAM causes mitochondrial oxidative phosphorylation dysfunction, resulting in increased ROS production and MMP activity (Mendelsohn and Larrick 2014) . We have shown the intimate interaction between intramitochondrial translocation of calpain 1, resulting in increased oxidative stress and MMP9 expression (Moshal et al. 2006) .
Invivo studies have analyzed the effects of TFAM overexpression, showing decreased myocyte hypertrophy, oxidative stress, protease expression, apoptosis, interstitial fibrosis, D r a f t increased mtDNA copy number, and cardiomyocyte stability in myocardial infarction/heart failure models (Hayashi et al. 2008; Ikeda et al. 2015; Ikeuchi et al. 2005; Kang et al. 2007 ).
Additionally, TFAM protected cells from oxidative stress in many invitro models (AguirreRueda et al. 2015; Thomas et al. 2012; Xu et al. 2009 ). Therefore, the purpose of this study is to elucidate TFAM's role in cardiomyocyte stability through protease and hypertrophic regulation.
Materials & Methods

Chemicals and Antibodies
TFAM overexpression and CRISPR vectors were purchased from Genecopia (Rockville, Maryland). All primary antibodies were purchased from Abcam (Cambridge, United Kingdom).
Horseradish peroxidase ( was blocked with a 5% milk solution for 1 hour. Primary antibodies were diluted at a concentration 1:1000 in TBST and incubated on the membrane overnight. All membranes were washed in TBST solution 4 times and then incubated with secondary HRP conjugated antibody solution for 1 hour at room temperature. Four TBST washing steps followed before membranes were developed using a chemiluminescent substrate in a BioRad Chemidoc (Hercules, Calif.).
Band intensity was determined using densitometry analysis. Beta-actin was used to normalize protein loading.
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Immunocytochemistry Post-cell treatment, media was aspirated from each well of the eight well chamber slide and cells were rinsed with PBS. Cells were fixed at room temperature in 4% paraformaldehyde solution for 20 min and washed 3 times with PBS. Blocking was performed with a mixed solution of 2% bovine-serum-albumin (BSA) and 0.025% Triton X-100. Cells were permeabolized for 1 hour. All primary antibodies were incubated in the chamber slide at a concentration of 1:100 overnight at 4 o C. The wells were aspirated, washed 3 times and incubated for 90 min with the secondary antibody (1:200) at room temp. The chamber slides were washed 3 times more, and DAPI was added at 1:10,000 for 10 min. This analysis was observed via Confocal microscopy.
Statistical Analysis
Data are expressed as means ± SE. Statistical analysis was performed by Graphpad Prism software using a one-way ANOVA followed by a Bonferoni comparison test. P<0.05 was considered statistically significant.
Results
CRISPR Vector Significantly Increases Serca2a and Calpain1 Protein Expression
To observe the efficacy of the TFAM overexpression vector and the CRISPR-Cas9 knockdown vector for TFAM, we analyzed TFAM expression with both treatments. Through western blotting and confocal analysis, we saw significant decreases in TFAM protein expression with the CRISPR vector compared to the control (p < 0.001) and the TFAM overexpression vector (p < 0.001). Additionally, the TFAM overexpression vector showed considerable increases in TFAM expression compared to control (p < 0.05) Fig. 1a & 3a .
Western blotting and confocal analysis were used to determine changes in Serca2a expression with both treatments. CRISPR vector significantly increased Serca2a expression in HL-1 cardiomyocytes as compared with the control groups (p < 0.001) Fig. 1b & 3b .
Confocal analysis and western blotting show the CRISPR vector greatly increased Calpain1 expression as compared to control groups (p < 0.001) Fig 1c & Serca2a expression is significantly higher. Therefore, calcium-driven calpain1 levels remain higher than the compensatory activity of the Serca2a pump.
Treatment of the CRISPR vector to HL-1 cardiomyocytes showed significantly increased MMP9 protein expression. MMP9, a ROS activated protease, is highly expressed in heart failure/hypoxic conditions (Ikeda et al. 2015) . Analysis of MMP9 expression in the CRISPR vector treatment group revealed a significantly high MMP9 expression when compared D r a f t to the control. This data suggests that lack of TFAM creates a ROS buildup, inducing MMP9 expression.
NFAT transcriptionally regulates the expression of the mitochondrial ROS-generating enzymes NADPH oxidases. NOX enzymes have been linked and noted as a leading source of ROS in cardiac pathologies (Sorescu and Griendling 2002) ; additionally, it is a stimulator of cardiac hypertrophy. Treatment with the CRISPR vector significantly increased NFAT4 expression compared to the control. As previously discussed, TFAM inhibits NFAT transcriptional activity; therefore, lack of TFAM prevents the inactivation of NFAT, resulting in increased expression.
We observed a comparison between the TFAM vector group and the CRISPR vector group that mimics invivo TFAM treatments. Bonferoni statistical analysis shows that TFAM treatment decreases Calpain1, MMP9, and NFAT in comparison to the CRISPR TFAM knockdown group. Using the CRISPR vector we mimic HF models, in which TFAM is vastly decreased, and the TFAM overexpression vector is a reflection of TFAM transgenic models that produce similar observations.
Invitro use of hydrogen peroxide mimics ischemia/hypoxic stress invivo models.
Physiological concentrations of hydrogen peroxide are between 0.1-0.2 micromolar and can reach 200 micromolar in pathological conditions (Giorgio et al. 2007 ). Studies show that 200 micromolar hydrogen peroxide is used to induce stress on HL-1 cardiomyocytes (Zhao et al. 2015) . In our treatment groups, we noticed a high cell death rate when administering 200 micromolar H 2 O 2 to the cells. Therefore, we lowered it to a working concentration of 127 micromolar for 6 hours, which was observed functional by trypan blue staining. Ali et al have shown that 200 micromolar H 2 O 2 administered to neonatal cardiomyoctes increased MMP levels after 4 hours of treatment (Ali et al. 2013 ).
Oxidative stress is a known stimulator of MMPs (Okamoto et al. 2001 
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